Lexeo Therapeutics, Inc. (LXEO) Key Metrics
LXEO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $216.7M
- Enterprise value
- $84.5M
- P/E (TTM)
- —
- Forward P/E
- 6.4
- PEG ratio
- —
- Price / sales
- 478.3
- Price / book
- 1.2 10-yr median 2.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.64
LXEO key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLXEO valuation Price multiples at each fiscal year-end price.
LXEO returns How much profit the business earns on the capital it uses.
LXEO per-share figures Results divided by the shares outstanding at year-end.
LXEO financial health Debt, liquidity and how easily interest is covered.
LXEO efficiency & capital use Working capital cycle and where the cash goes.
LXEO valuation history
LXEO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LXEO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LXEO cash returned to shareholders
LXEO price vs earnings per share
LXEO key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $532.7M | $209.2M | $357.6M | — | — | — |
| Enterprise value | $358.8M | $97.6M | $247.8M | — | — | — |
| Price / book | 2.2 | 1.8 | 3.1 | — | — | — |
| Earnings yield | −18.8% | −47.0% | −18.6% | — | — | — |
| Free cash flow yield | −18.6% | −39.0% | −16.7% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $9.93 | $6.58 | $13.42 | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.03 | $0.07 | $0.02 |
| Earnings per share | −$1.86 | −$3.09 | −$2.49 | −$2.36 | −$2.01 | −$0.20 |
| Operating cash flow per share | −$1.84 | −$2.55 | −$2.23 | −$2.17 | −$1.76 | −$0.12 |
| Free cash flow per share | −$1.84 | −$2.57 | −$2.24 | −$2.20 | −$1.76 | −$0.12 |
| Cash per share | $3.39 | $3.82 | $4.56 | $3.07 | $5.40 | $1.17 |
| Book value per share | $4.60 | $3.68 | $4.26 | −$4.49 | −$2.21 | −$0.22 |
| Tangible book value per share | $4.60 | $3.68 | $4.26 | −$4.49 | −$2.21 | −$0.22 |
| Capex per share | $0.01 | $0.02 | $0.01 | $0.04 | $0.01 | $0.00 |
| Debt per share | $0.15 | $0.31 | $0.44 | $0.54 | $0.17 | $0.12 |
| Shares outstanding | 53.6M | 31.8M | 26.6M | 25.2M | 25.2M | 25.2M |
| Change in shares outstanding | +68.8% | +19.3% | +5.9% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −55.0% | −85.4% | — | — | — | — |
| Return on invested capital (ROIC) | −221.2% | — | — | — | — | — |
| Return on assets (ROA) | −48.1% | −68.6% | −56.1% | −50.7% | −60.9% | −17.5% |
| Return on tangible assets | −37.2% | −66.9% | −47.5% | −61.1% | −37.0% | −17.5% |
| Free cash flow margin | — | — | — | — | — | −604.3% |
| Financial health | ||||||
| Total debt | $7.9M | $9.9M | $11.6M | $13.5M | $4.3M | $3.0M |
| Cash & short-term investments | $181.8M | $121.5M | $121.5M | $77.3M | $135.9M | $29.4M |
| Net debt | −$173.9M | −$111.6M | −$109.8M | −$63.9M | −$131.5M | −$26.4M |
| Debt / equity | 0.03 | 0.08 | 0.10 | — | — | — |
| Debt / assets | 0.03 | 0.07 | 0.08 | 0.14 | 0.03 | 0.10 |
| Current ratio | 11.21 | 5.52 | 7.21 | 5.58 | 18.35 | 42.15 |
| Quick ratio | 11.21 | 5.52 | 7.21 | 5.58 | 18.35 | 42.15 |
| Interest coverage | -530.4 | -927.8 | -334.2 | -664.9 | — | -31.2 |
| Working capital | $171.6M | $103.3M | $107.1M | $65.7M | $129.2M | $28.7M |
| Invested capital | $72.8M | $5.2M | $3.7M | −$176.8M | −$187.2M | −$31.9M |
| Tangible asset value | $246.7M | $116.8M | $113.5M | −$113.0M | −$55.6M | −$5.5M |
| Net current asset value | $166.4M | $96.0M | $98.0M | −$130.0M | −$55.8M | −$5.5M |
| Graham net-net per share | $2.98 | $2.88 | $3.57 | −$5.27 | −$2.25 | −$0.22 |
| Capital allocation | ||||||
| Share buybacks (net) | $0 | $17,000 | $0 | — | — | — |
| Capex / revenue | — | — | — | 137.8% | 11.3% | 0.0% |
| Capex / depreciation | 0.19 | 0.24 | 0.09 | 0.79 | 14.46 | 0.00 |
| Stock-based compensation / revenue | — | — | — | 272.3% | 23.3% | 0.0% |
| R&D / revenue | — | — | — | 7,517.1% | 2,723.1% | 833.0% |
| SG&A / revenue | — | — | — | 1,835.0% | 433.7% | 151.9% |
| Efficiency | ||||||
| Days payables outstanding | 989.6 | 930.8 | 640.9 | 914.7 | 42,276.8 | — |
| Payables turnover | 0.37 | 0.39 | 0.57 | 0.40 | 0.01 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 |
| Average payables | $5.6M | $5.1M | $3.2M | $2.9M | $1.6M | $44,319 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from LXEO's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LXEO valuation and financial ratios
Lexeo Therapeutics earned a return on equity of −55.0% and a return on invested capital of −221.2% in fiscal 2025. It ended the year with $7.9 million of debt and $181.8 million in cash and short-term investments, a net cash position of $173.9 million. The share count rose 113.1% from 25.2M to 53.6M over 5 years.
See the LXEO income statement, the LXEO chart for price history, or the LXEO stock overview for the latest quote and news.
LXEO key metrics FAQ
What is Lexeo Therapeutics's return on equity?
Lexeo Therapeutics's return on equity (ROE) was −55.0% in fiscal 2025: net income of -$100.0 million on average shareholders' equity of $181.8 million.
What is Lexeo Therapeutics's ROIC?
Lexeo Therapeutics's return on invested capital was −221.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Lexeo Therapeutics have?
Lexeo Therapeutics had total debt of $7.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is Lexeo Therapeutics's free cash flow yield?
Lexeo Therapeutics generated -$99.0 million of free cash flow in fiscal 2025, a free cash flow yield of −18.6% on its market value at year-end ($532.7 million).
What is Lexeo Therapeutics's current ratio?
Lexeo Therapeutics's current ratio was 11.21 at the end of fiscal 2025: current assets were 11.21 times current liabilities.